|
1
|
Paez JG, Jänne PA, Lee JC, Tracy S,
Greulich H, Gabriel S, Herman P, Kaye FJ, Lindeman N, Boggon TJ, et
al: EGFR mutations in lung cancer: Correlation with clinical
response to gefitinib therapy. Science. 304:1497–1500. 2004.
View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Lynch TJ, Bell DW, Sordella R,
Gurubhagavatula S, Okimoto RA, Brannigan BW, Harris PL, Haserlat
SM, Supko JG, Haluska FG, et al: Activating mutations in the
epidermal growth factor receptor underlying responsiveness of
non-small-cell lung cancer to gefitinib. N Engl J Med.
350:2129–2139. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Tan DS, Mok TS and Rebbeck TR: Cancer
genomics: Diversity and disparity across ethnicity and geography. J
Clin Oncol. 34:91–101. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Tan DS, Yom SS, Tsao MS, Pass HI, Kelly K,
Peled N, Yung RC, Wistuba II, Yatabe Y, Unger M, et al: The
International Association for the Study of Lung Cancer consensus
statement on optimizing management of EGFR mutation-positive
non-small cell lung cancer: Status in 2016. J Thorac Oncol.
11:946–963. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Masters GA, Temin S, Azzoli CG, Giaccone
G, Baker S Jr, Brahmer JR, Ellis PM, Gajra A, Rackear N, Schiller
JH, et al: Systemic Therapy for Stage IV Non-Small-Cell Lung
Cancer: American Society of Clinical Oncology Clinical Practice
Guideline Update. J Clin Oncol. 33:3488–3515. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Kuan FC, Kuo LT, Chen MC, Yang CT, Shi CS,
Teng D and Lee KD: Overall survival benefits of first-line EGFR
tyrosine kinase inhibitors in EGFR-mutated non-small-cell lung
cancers: A systematic review and meta-analysis. Br J Cancer.
113:1519–1528. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Mok TS, Wu YL, Thongprasert S, Yang CH,
Chu DT, Saijo N, Sunpaweravong P, Han B, Margono B, Ichinose Y, et
al: Gefitinib or carboplatin-paclitaxel in pulmonary
adenocarcinoma. N Engl J Med. 361:947–957. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Maemondo M, Inoue A, Kobayashi K, Sugawara
S, Oizumi S, Isobe H, Gemma A, Harada M, Yoshizawa H, Kinoshita I,
et al: North-East Japan Study Group: Gefitinib or chemotherapy for
non-small-cell lung cancer with mutated EGFR. N Engl J Med.
362:2380–2388. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Zhou C, Wu YL, Chen G, Feng J, Liu XQ,
Wang C, Zhang S, Wang J, Zhou S, Ren S, et al: Erlotinib versus
chemotherapy as first-line treatment for patients with advanced
EGFR mutation-positive non-small-cell lung cancer (OPTIMAL,
CTONG-0802): A multicentre, open-label, randomised, phase 3 study.
Lancet Oncol. 12:735–742. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Yang JC, Wu YL, Schuler M, Sebastian M,
Popat S, Yamamoto N, Zhou C, Hu CP, O'Byrne K, Feng J, et al:
Afatinib versus cisplatin-based chemotherapy for EGFR
mutation-positive lung adenocarcinoma (LUX-Lung 3 and LUX-Lung 6):
Analysis of overall survival data from two randomised, phase 3
trials. Lancet Oncol. 16:141–151. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Mitsudomi T, Morita S, Yatabe Y, Negoro S,
Okamoto I, Tsurutani J, Seto T, Satouchi M, Tada H, Hirashima T, et
al: West Japan Oncology Group: Gefitinib versus cisplatin plus
docetaxel in patients with non-small-cell lung cancer harbouring
mutations of the epidermal growth factor receptor (WJTOG3405): An
open label, randomised phase 3 trial. Lancet Oncol. 11:121–128.
2010. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Bean GR, Ganesan YT, Dong Y, Takeda S, Liu
H, Chan PM, Huang Y, Chodosh LA, Zambetti GP, Hsieh JJ, et al: PUMA
and BIM are required for oncogene inactivation-induced apoptosis.
Sci Signal. 6:ra202013. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Isobe K, Kakimoto A, Mikami T, Kaburaki K,
Kobayashi H, Yoshizawa T, Makino T, Otsuka H, Sano GO, Sugino K, et
al: Association of BIM deletion polymorphism and BIM-γ RNA
expression in NSCLC with EGFR mutation. Cancer Genomics Proteomics.
13:475–482. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Costa C, Molina MA, Drozdowskyj A,
Giménez-Capitán A, Bertran-Alamillo J, Karachaliou N, Gervais R,
Massuti B, Wei J, Moran T, et al: The impact of EGFR T790M
mutations and BIM mRNA expression on outcome in patients with
EGFR-mutant NSCLC treated with erlotinib or chemotherapy in the
randomized phase III EURTAC trial. Clin Cancer Res. 20:2001–2010.
2014. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Garofalo M, Romano G, Di Leva G, Nuovo G,
Jeon YJ, Ngankeu A, Sun J, Lovat F, Alder H, Condorelli G, et al:
EGFR and MET receptor tyrosine kinase-altered microRNA expression
induces tumorigenesis and gefitinib resistance in lung cancers. Nat
Med. 18:74–82. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Naumov GN, Nilsson MB, Cascone T, Briggs
A, Straume O, Akslen LA, Lifshits E, Byers LA, Xu L, Wu HK, et al:
Combined vascular endothelial growth factor receptor and epidermal
growth factor receptor (EGFR) blockade inhibits tumor growth in
xenograft models of EGFR inhibitor resistance. Clin Cancer Res.
15:3484–3494. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Hirsch FR, Varella-Garcia M and Cappuzzo
F: Predictive value of EGFR and HER2 overexpression in advanced
non-small-cell lung cancer. Oncogene. 28 Suppl 1:S32–S37. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Rho JK, Choi YJ, Lee JK, Ryoo BY, Na II,
Yang SH, Lee SS, Kim CH, Yoo YD and Lee JC: The role of MET
activation in determining the sensitivity to epidermal growth
factor receptor tyrosine kinase inhibitors. Mol Cancer Res.
7:1736–1743. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Agata Y, Kawasaki A, Nishimura H, Ishida
Y, Tsubata T, Yagita H and Honjo T: Expression of the PD-1 antigen
on the surface of stimulated mouse T and B lymphocytes. Int
Immunol. 8:765–772. 1996. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Nishimura H and Honjo T: PD-1: An
inhibitory immunoreceptor involved in peripheral tolerance. Trends
Immunol. 22:265–268. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Watanabe N, Gavrieli M, Sedy JR, Yang J,
Fallarino F, Loftin SK, Hurchla MA, Zimmerman N, Sim J, Zang X, et
al: BTLA is a lymphocyte inhibitory receptor with similarities to
CTLA-4 and PD-1. Nat Immunol. 4:670–679. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Keir ME, Butte MJ, Freeman GJ and Sharpe
AH: PD-1 and its ligands in tolerance and immunity. Annu Rev
Immunol. 26:677–704. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Brahmer J, Reckamp KL, Baas P, Crinò L,
Eberhardt WE, Poddubskaya E, Antonia S, Pluzanski A, Vokes EE,
Holgado E, et al: Nivolumab versus docetaxel in advanced
squamous-cell non-small-cell lung cancer. N Engl J Med.
373:123–135. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Borghaei H, Paz-Ares L, Horn L, Spigel DR,
Steins M, Ready NE, Chow LQ, Vokes EE, Felip E, Holgado E, et al:
Nivolumab versus docetaxel in advanced nonsquamous non-small-cell
lung cancer. N Engl J Med. 373:1627–1639. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Herbst RS, Baas P, Kim DW, Felip E,
Pérez-Gracia JL, Han JY, Molina J, Kim JH, Arvis CD, Ahn MJ, et al:
Pembrolizumab versus docetaxel for previously treated,
PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010):
A randomised controlled trial. Lancet. 387:1540–1550. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Afreen S and Dermime S: The
immunoinhibitory B7-H1 molecule as a potential target in cancer:
Killing many birds with one stone. Hematol Oncol Stem Cell Ther.
7:1–17. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Boland JM, Kwon ED, Harrington SM,
Wampfler JA, Tang H, Yang P and Aubry MC: Tumor B7-H1 and B7-H3
expression in squamous cell carcinoma of the lung. Clin Lung
Cancer. 14:157–163. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Konishi J, Yamazaki K, Azuma M, Kinoshita
I, Dosaka-Akita H and Nishimura M: B7-H1 expression on non-small
cell lung cancer cells and its relationship with tumor-infiltrating
lymphocytes and their PD-1 expression. Clin Cancer Res.
10:5094–5100. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Chen YY, Wang LB, Zhu HL, Li XY, Zhu YP,
Yin YL, Lü FZ, Wang ZL and Qu JM: Relationship between programmed
death-ligand 1 and clinicopathological characteristics in non-small
cell lung cancer patients. Chin Med Sci J. 28:147–151. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Mu CY, Huang JA, Chen Y, Chen C and Zhang
XG: High expression of PD-L1 in lung cancer may contribute to poor
prognosis and tumor cells immune escape through suppressing tumor
infiltrating dendritic cells maturation. Med Oncol. 28:682–688.
2011. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Akbay EA, Koyama S, Carretero J, Altabef
A, Tchaicha JH, Christensen CL, Mikse OR, Cherniack AD, Beauchamp
EM, Pugh TJ, et al: Activation of the PD-1 pathway contributes to
immune escape in EGFR-driven lung tumors. Cancer Discov.
3:1355–1363. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Azuma K, Ota K, Kawahara A, Hattori S,
Iwama E, Harada T, Matsumoto K, Takayama K, Takamori S, Kage M, et
al: Association of PD-L1 overexpression with activating EGFR
mutations in surgically resected nonsmall-cell lung cancer. Ann
Oncol. 25:1935–1940. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Chen N, Fang W, Zhan J, Hong S, Tang Y,
Kang S, Zhang Y, He X, Zhou T, Qin T, et al: Upregulation of PD-L1
by EGFR activation mediates the immune escape in EGFR-driven NSCLC:
Implication for optional immune targeted therapy for NSCLC patients
with EGFR mutation. J Thorac Oncol. 10:910–923. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Dronca RS, Liu X, Harrington SM, Chen L,
Cao S, Kottschade LA, McWilliams RR, Block MS, Nevala WK, Thompson
MA, et al: T cell Bim levels reflect responses to anti-PD-1 cancer
therapy. JCI Insight. 1:12016. View Article : Google Scholar
|
|
35
|
Joseph RW, Parasramka M, Eckel-Passow JE,
Serie D, Wu K, Jiang L, Kalari K, Thompson RH, Ho Huu T, Castle EP,
et al: Inverse association between programmed death ligand 1 and
genes in the VEGF pathway in primary clear cell renal cell
carcinoma. Cancer Immunol Res. 1:378–385. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Vandesompele J, De Preter K, Pattyn F,
Poppe B, Van Roy N, De Paepe A and Speleman F: Accurate
normalization of real-time quantitative RT-PCR data by geometric
averaging of multiple internal control genes. Genome Biol.
3:RESEARCH00342002. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Wong ML and Medrano JF: Real-time PCR for
mRNA quantitation. Biotechniques. 39:75–85. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
D'Incecco A, Andreozzi M, Ludovini V,
Rossi E, Capodanno A, Landi L, Tibaldi C, Minuti G, Salvini J,
Coppi E, et al: PD-1 and PD-L1 expression in molecularly selected
non-small-cell lung cancer patients. Br J Cancer. 112:95–102. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Tang Y, Fang W, Zhang Y, Hong S, Kang S,
Yan Y, Chen N, Zhan J, He X, Qin T, et al: The association between
PD-L1 and EGFR status and the prognostic value of PD-L1 in advanced
non-small cell lung cancer patients treated with EGFR-TKIs.
Oncotarget. 6:14209–14219. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Lin C, Chen X, Li M, Liu J, Qi X, Yang W,
Zhang H, Cai Z, Dai Y and Ouyang X: Programmed death-ligand 1
expression predicts tyrosine kinase inhibitor response and better
prognosis in a cohort of patients with epidermal growth factor
receptor mutation-positive lung adenocarcinoma. Clin Lung Cancer.
16:e25–e35. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Gong Y, Somwar R, Politi K, Balak M,
Chmielecki J, Jiang X and Pao W: Induction of BIM is essential for
apoptosis triggered by EGFR kinase inhibitors in mutant
EGFR-dependent lung adenocarcinomas. PLoS Med. 4:e2942007.
View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Gibbons RM, Liu X, Pulko V, Harrington SM,
Krco CJ, Kwon ED and Dong H: B7-H1 limits the entry of effector
CD8(+) T cells to the memory pool by upregulating Bim.
Oncoimmunology. 1:1061–1073. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Huang Y, Goel S, Duda DG, Fukumura D and
Jain RK: Vascular normalization as an emerging strategy to enhance
cancer immunotherapy. Cancer Res. 73:2943–2948. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
44
|
Wei J, Wu A, Kong LY, Wang Y, Fuller G,
Fokt I, Melillo G, Priebe W and Heimberger AB: Hypoxia potentiates
glioma-mediated immunosuppression. PLoS One. 6:e161952011.
View Article : Google Scholar : PubMed/NCBI
|
|
45
|
Ott PA, Hodi FS and Buchbinder EI:
Inhibition of immune checkpoints and vascular endothelial growth
factor as combination therapy for metastatic melanoma: An overview
of rationale, preclinical evidence, and initial clinical data.
Front Oncol. 5:2022015. View Article : Google Scholar : PubMed/NCBI
|
|
46
|
Huang Y, Yuan J, Righi E, Kamoun WS,
Ancukiewicz M, Nezivar J, Santosuosso M, Martin JD, Martin MR,
Vianello F, et al: Vascular normalizing doses of antiangiogenic
treatment reprogram the immunosuppressive tumor microenvironment
and enhance immunotherapy. Proc Natl Acad Sci USA. 109:17561–17566.
2012. View Article : Google Scholar : PubMed/NCBI
|
|
47
|
Zou W and Chen L: Inhibitory B7-family
molecules in the tumour microenvironment. Nat Rev Immunol.
8:467–477. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
48
|
Chen J, Jiang CC, Jin L and Zhang XD:
Regulation of PD-L1: A novel role of pro-survival signalling in
cancer. Ann Oncol. 27:409–416. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
49
|
Okita R, Maeda A, Shimizu K, Nojima Y,
Saisho S and Nakata M: PD-L1 overexpression is partially regulated
by EGFR/HER2 signaling and associated with poor prognosis in
patients with non-small-cell lung cancer. Cancer Immunol
Immunother. 66:865–876. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
50
|
Shimoji M, Shimizu S, Sato K, Suda K,
Kobayashi Y, Tomizawa K, Takemoto T and Mitsudomi T: Clinical and
pathologic features of lung cancer expressing programmed cell death
ligand 1 (PD-L1). Lung Cancer. 98:69–75. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
51
|
Han JJ, Kim DW, Koh J, Keam B, Kim TM,
Jeon YK, Lee SH, Chung DH and Heo DS: Change in PD-L1 expression
after acquiring resistance to gefitinib in EGFR-mutant
non-small-cell lung cancer. Clin Lung Cancer. 17:263–270.e262.
2016. View Article : Google Scholar : PubMed/NCBI
|
